email article
A sequential augmented reduced-intensity conditioning (RIC) regimen failed to improve post-transplant outcomes for patients with high-risk acute myeloid leukemia (AML) or myelodysplasia (MDS), a randomized trial showed.
Neither 2-year overall survival (OS) nor cumulative incidence of relapse improved as compared with standard RIC prior to allogeneic hematopoietic cell transplant (HCT). Detectable measurable residual disease (MRD) prior to transplant was associated with a twofold increase in relapse, but the data showed no evidence of interaction between MRD status and conditioning regimen, reported Charles Craddock, MD, of Queen Elizabeth Hospital in Birmingham, England, and co-authors in the In unrandomized phase II trials and retrospective registry data, the [intensified] protocol, which incorporates additional cytoreductive chemotherapy prior to a fludarabine-based RIC regimen, has been reported to reduce relapse and improve outcomes in high-risk AML or MD